Source: Davit Kirakosyan
Needham Analysts Downgrade Biogen
Biogen (NASDAQ:BIIB), a leading biotechnology company, has had its rating downgraded from ‘Buy’ to ‘Hold’ by Needham analysts. This decision is primarily due to limited upside potential for the stock over the next year. The analysts cite slower-than-expected growth from new products and a lack of significant pipeline developments in the near term as their primary reasons for the downgrade. This downgrade suggests that the stock may not be a lucrative investment in the short term.
Slower Growth from New Products
One of the key reasons for the downgrade is the slower growth rate projected for Leqembi, a critical Alzheimer’s treatment in Biogen’s portfolio. The analysts found that physician feedback indicated a gradual adoption of the drug, implying a slower sales pace than initially expected. This slower uptake could significantly impact the company’s revenue growth, as Leqembi is one of the significant products in Biogen’s portfolio.
As a result of this slower growth, the analysts have decided to lower the 2025 and 2026 Leqembi sales estimates, placing them significantly below consensus forecasts. This is a clear indicator of the challenges the company is likely to face in driving up its revenues in the next few years.
Revenue Growth and New Product Launches
According to Needham’s analysts, Biogen’s revenue was not expected to return to growth until 2026. The company is likely to experience a decline of 1.6% in 2024 and flat performance in 2025. This projection can be attributed to the ramp-up of new product launches—Leqembi, Skyclarys, and Zurzuvae—struggling to fully offset declines in the base business.
This projection suggests that while the company is investing in new products and attempting to diversify its revenue streams, these efforts may not be enough to counter the decline in its base business in the short term. This situation further underscores the challenges facing Biogen and justifies the downgrade by Needham analysts.
Limited Catalysts in Near-Term Pipeline
Biogen’s near-term pipeline also offered limited catalysts, with only Litifilimab’s two Phase 3 studies in systemic lupus erythematosus (SLE) expected to deliver results within the next year. Even if these trials yield positive outcomes, the analysts estimate that the impact on the stock would be modest.
This projection indicates a lack of significant positive news that could potentially drive the stock’s price up in the short term. It also suggests that Biogen’s near-term prospects may be limited, adding to the reasons for the downgrade.
Long-Term Growth Potential Remains Intact
Despite the downgrade and the challenges facing Biogen in the short term, the analysts believe that the company’s longer-term growth potential remains intact. This growth is supported by promising pipeline developments and further advancements in key product launches beyond 2026. However, the lack of short-term drivers prompted a more cautious outlook from the analysts.
This cautious approach indicates that while Biogen may face challenges in the short term, the company’s long-term prospects remain promising. Investors with a long-term perspective may still find value in the stock, despite the recent downgrade.
In conclusion, while the downgrade by Needham analysts suggests challenges for Biogen in the short term, the company’s long-term prospects remain intact. Investors should keep an eye on the company’s developments and consider their investment horizons when making decisions regarding this stock.